利瑞鲁单抗

利瑞鲁单抗

单克隆抗体
种类	完整抗体
目標	KIR2DL1/2/3
臨床資料
ATC碼	未分配
识别信息
CAS号	1000676-41-4
ChemSpider	none
UNII	S9XDI9W918
KEGG	D10444
化学信息
化学式	C6452H9918N1698O2030S46
摩尔质量	145,228.93 g·mol^−1

利瑞鲁单抗（INN：lirilumab）是一种人单克隆抗体，设计用于治疗癌症。[1]它与KIR2DL1/2/3结合来发挥作用。[2]

该药物由Innate Pharma开发，并授权给百时美施贵宝。

临床试验

一项针对急性骨髓性白血病的II期临床试验[3]于2017年提前终止（“失败”）。[4]

该药物已注册用于头颈鳞状细胞癌（SCCHN）的试验，[5]但可能会被放弃。[6]

截至2017年11月 (2017-11)^[update]，九项利瑞鲁单抗临床试验已注册为活跃状态。[7]

参考资料

1. Statement On A Nonproprietary Name Adopted By The USAN Council - Lirilumab （页面存档备份，存于互联网档案馆）, American Medical Association.
2. Romagné F, André P, Spee P, Zahn S, Anfossi N, Gauthier L, Capanni M, Ruggeri L, Benson DM, Blaser BW, Della Chiesa M, Moretta A, Vivier E, Caligiuri MA, Velardi A, Wagtmann N. Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells. Blood. September 2009, 114 (13): 2667–77. PMC 2756126 . PMID 19553639. doi:10.1182/blood-2009-02-206532. 
3. Clinical trial number NCT01687387 for "Efficacy Study of Anti-KIR Monoclonal Antibody as Maintenance Treatment in Acute Myeloid Leukemia (EFFIKIR)" at ClinicalTrials.gov
4. Innate Pharma Leukemia Candidate Lirilumab Fails Phase II Trial. Feb 2017. [2024-05-26]. （原始内容存档于2017-12-01）. 
5. Clinical trial number NCT03341936 for "Adjuvant Nivolumab and Lirilumab in Patients With Relapsed, Resectable Squamous Cell Carcinoma of the Head and Neck " at ClinicalTrials.gov
6. Bad news for Innate Pharma as BMS-backed drug stumbles nov 2017. [2024-05-26]. （原始内容存档于2023-12-29）. 
7. lirilumab trials. [2024-05-26]. （原始内容存档于2018-11-05）.